Abstract
The growth arrest and DNA damage inducible protein 45 (GADD45) family comprises stress-induced nuclear proteins that interact with DNA demethylases to facilitate DNA demethylation, thereby regulating diverse cellular processes including oxidative stress, DNA damage repair, apoptosis, proliferation, differentiation, inflammation, and neuroplasticity by modulating the expression patterns of specific genes. Widely expressed in the central nervous system, the GADD45 family plays a pivotal role in various neurological disorders, rendering it a potential therapeutic target for central nervous system diseases. This review presented a comprehensive overview of the expression patterns and potential mechanisms of action associated with each member of GADD45 family (GADD45α, GADD45β, and GADD45γ) in neurodevelopmental, neurodegenerative, and neuropsychiatric disorders, while also explored strategies to harness these mechanisms for intervention and treatment. Future research should prioritize the development of effective modulators targeting the GADD45 family for clinical trials aimed at treating central nervous system diseases.
Introduction
Neurological and psychiatric disorders often arise from a complex interplay between genetic susceptibility and environmental stressors. A key interface in this relationship is epigenetics, specifically DNA methylation. While the addition of methyl groups (silencing) is well-studied, the mechanisms of active DNA demethylation—the process of "unlocking" gene expression—are less understood. The GADD45 family (α, β, and γ) has emerged as a critical "stress sensor" that bridges environmental stimuli with epigenetic regulation in the brain.
The GADD45 Family as Epigenetic Gatekeepers
GADD45 proteins are nuclear factors that do not possess enzymatic activity themselves but act as recruiters. They bring DNA demethylase enzymes, such as Ten-Eleven Translocation (TET) proteins and Thymine DNA Glycosylase (TDG), to specific gene promoters. This recruitment facilitates the removal of methyl groups, effectively resetting the epigenetic state of a neuron in response to stress.
As illustrated above, DNA methylation (Panel A) typically inhibits transcription. GADD45 proteins (Panel B) are essential for the active demethylation pathway, working with TETs and the Base Excision Repair (BER) machinery to restore gene activity. This process is vital for regulating genes like BDNF, which are essential for neuronal survival and plasticity.
Methodology and Data Synthesis
This comprehensive review synthesizes data across three primary levels of investigation:
- Clinical Data: Analysis of human patient tissues, such as prefrontal cortex biopsies from Schizophrenia patients and peripheral blood from children with Autism Spectrum Disorder (ASD).
- In Vivo Models: Studies using animal models like the APP/PS1 mouse (Alzheimer’s) and the BTBR inbred strain (Autism).
- In Vitro Systems: Mechanistic studies in neuronal cell lines (e.g., PC12, HT22) to observe signaling cascades like MAPK, JNK, and p38.
The authors specifically focus on the GADD45-TET-TDG pathway as the primary biological machinery for active DNA demethylation in the central nervous system.
Key Insights Across Disorders
The GADD45 family exhibits functional heterogeneity, with different isoforms playing distinct roles depending on the disease context.
Neurodevelopmental Disorders
In Schizophrenia (SCZ), GADD45β expression is significantly diminished in the prefrontal cortex. This leads to hypermethylation and subsequent silencing of the BDNF gene, contributing to the cognitive deficits associated with the disorder.
Neurodegenerative Disorders
In Alzheimer’s Disease (AD), GADD45α shows a biphasic response: it is downregulated in early stages but upregulated in later stages as neurons attempt to cope with amyloid-beta toxicity. In Parkinson’s Disease (PD), GADD45γ has been linked to sex-specific signaling via the SRY gene on the Y chromosome, potentially explaining differences in disease prevalence between sexes.
Neuropsychiatric Disorders
Major Depressive Disorder (MDD) is associated with a widespread decrease in GADD45α, β, and γ in the hippocampus. Conversely, addictive substances like cocaine trigger a rapid increase in GADD45β in the brain's reward centers, facilitating the epigenetic remodeling that drives addiction.
Therapeutic Potential and Future Directions
Interestingly, common treatments such as Electroconvulsive Therapy (ECT) and Valproic Acid (VPA) have been shown to trigger an upregulation of GADD45. This suggests that the clinical efficacy of these interventions may be partially due to GADD45-mediated epigenetic remodeling.
Despite these insights, challenges remain. There is a lack of isoform-specific research (particularly for α and γ) and regional inconsistencies in expression patterns. The authors conclude that future research must prioritize the development of highly specific small-molecule modulators of the GADD45 family to move from descriptive observations to effective clinical interventions.
Summary updated